Pentadeca Arginate (PDA) is a synthetic pentadecapeptide — a salt-form variant of BPC-157. It has the identical 15-amino-acid sequence (GEPPPGKPADDAGLV) but is formulated with an arginate (arginine) counterion instead of the usual acetate. It is also sold as "Pentadeca Arginate Complex," "PDA," or "BPC-157 Arginate."
Synthetic pentadecapeptide; an arginate salt form of BPC-157. Single compound.
PDA shares the exact 15-amino-acid sequence of BPC-157 (GEPPPGKPADDAGLV); the only difference is the salt/counterion (arginate vs acetate). Its proposed mechanism is therefore BPC-157's: promotion of angiogenesis and tissue repair, modulation of growth-factor pathways (notably upregulation of VEGFR2 and the nitric-oxide system), and cytoprotective effects on gut, tendon, muscle and nerve in animal models. The arginate salt is claimed to improve stability; the biological action is presumed identical because the active sequence is unchanged.
The crucial honest point: no peer-reviewed study has investigated Pentadeca Arginate as a distinct molecule. Every claim about PDA is inferred from the BPC-157 literature, which is itself almost entirely preclinical (rodent models of tendon, ligament, muscle, gut and nerve healing) with no large, controlled human trials. The "PDA-specific" evidence that vendors imply does not exist. Database searches for "PDA"/"arginate" return unrelated work — patent ductus arteriosus, pancreatic adenocarcinoma, heme arginate — none about this peptide.
No human clinical trial has established administration parameters for Pentadeca Arginate; VialTalk does not provide community-sourced dosing.
Not approved for human use; sold research-use-only. No regulated safety data exist for the arginate form. BPC-157 shows a generally benign profile in animal studies but lacks human safety trials, and the FDA has placed BPC-157 in the category of substances that do not qualify for compounding. The widely repeated "1,000x more stable at pH 3.0" claim is compounding-pharmacy marketing and has not been published in any peer-reviewed journal.
Despite a large indexed-document count, there is zero direct research on Pentadeca Arginate as a molecule. All plausible activity is inferred from BPC-157's mostly-preclinical record. Treat PDA as "BPC-157 in a different salt"; weight any claim to BPC-157's evidence — itself preclinical-dominant with no human trials. The enhanced-stability selling point is unverified.
"Pentadeca" = 15 (a pentadecapeptide); "Arginate" = arginine salt. Same active sequence as BPC-157, marketed as more stable (especially in oral formulations). Buyers are purchasing BPC-157 in an arginate salt, not a novel compound with its own evidence base. For mechanism and the (preclinical) research, the BPC-157 monograph is the canonical reference.
